Amyloidosis is a rare disease in which insoluble amyloid proteins are deposited in tissues or organs, resulting in organ damage. The diagnosis and treatment of this disease remain a major challenge, with several novel agents being explored in clinical trials. Furthermore, clinicians and researchers are drawing attention to the important role of the multidisciplinary team (MDT) in the treatment and management of patients.
In this podcast, experts Meral Beksac, MD, Ankara University, Ankara, Turkey, Shaji Kumar, MD, Mayo Clinic, Rochester, MN, and Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, discuss recent updates in the treatment and management of amyloidosis, and further highlight the importance of the MDT in this disease.
EHA 2021: key trial updates in myeloma
Key updates on CAR-T therapy for ALL
The Myeloma Sessions: post-COMY 2021 myeloma patients session
EHA 2021: MRD in myeloma
Latest updates on CAR-T therapy for CLL
The Myeloma Sessions: post-COMy 2021 roundtable
Focus on ALL: treating older patients, Ph-like ALL & post-transplant interventions
MDS Session: Women in Science
Key updates on CAR-T & cellular therapy for AML
The MDS Sessions: highlights from ASH 2020
The Transplant Sessions: ASH 2020 highlights
The Lymphoma Sessions: ASH 2020 highlights
Latest updates in Hodgkin lymphoma from ISHL HL 2021
The Myeloma Sessions: Post-ASH 2020 UK Discussion
The Post-EBMT for Trainees VJSessions
Post-ASH Amyloidosis Session from VJHemOnc
The Post EBMT VJSessions from VJHemOnc
Post-EBMT Highlights in Acute Myeloid Leukemia
The CLL Sessions: highlights from ASH 2020
The Lymphoma Sessions: highlights from ASH 2020
Create your
podcast in
minutes
It is Free
The Relaxback UK Show
Good Nurse Bad Nurse
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive